The combination of LSD1i with JAK/STAT pathway inhibitor (JAKi, Ruxolitinib) reversed efficiently the expression ratio of BCL2/BIM (anti-/pro-apoptotic) in human and mouse ETP-ALL. Here, SOAT1 is linked to acute lymphoblastic leukemia.